CSIMarket
 
Reviva Pharmaceuticals Holdings Inc   (RVPH)
Other Ticker:  
 
 
Price: $3.1500 $0.26 8.997%
Day's High: $3.16 Week Perf: -5.12 %
Day's Low: $ 2.80 30 Day Perf: -29.37 %
Volume (M): 311 52 Wk High: $ 9.25
Volume (M$): $ 978 52 Wk Avg: $4.89
Open: $2.83 52 Wk Low: $2.80



 Market Capitalization (Millions $) 76
 Shares Outstanding (Millions) 24
 Employees 12
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -38
 Cash Flow (TTM) (Millions $) -25
 Capital Exp. (TTM) (Millions $) 0

Reviva Pharmaceuticals Holdings Inc
Reviva Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company that is headquartered in San Francisco, California, United States. The company is focused on developing best-in-class small molecule therapeutics that target GPCRs (G Protein-Coupled Receptors), which are membrane-bound proteins that are involved in several physiological processes in the human body.

Reviva is dedicated to the discovery, development, and commercialization of therapeutics for serious and life-threatening medical conditions. The company has developed a pipeline of novel drug candidates that target various GPCRs involved in inflammation, fibrosis, and other diseases. Reviva's lead drug candidate, RP5063, is a dopamine-serotonin system targeted drug to enhance brain-derived neurotrophic factor (BDNF) signaling for various CNS diseases, such as schizophrenia, bipolar disorder, and major depressive disorder.

Reviva Pharmaceuticals Holdings was founded in 2005 by Dr. Laxminarayan Bhat, a former Merck scientist, with a vision to develop drugs that target GPCRs to treat various diseases. The company went public in 2020 under the trading symbol "RVPH" on the NASDAQ stock exchange.

Reviva has a world-class team of scientists and advisors with deep expertise in GPCRs and drug discovery. The company has also established several collaborations and partnerships with leading academic institutions and biotech companies to advance its drug discovery efforts.

In conclusion, Reviva Pharmaceuticals Holdings Inc is a biotech company that is dedicated to developing novel small molecule therapeutics that target GPCRs to treat serious and life-threatening medical conditions. The company's focus on developing drugs that target GPCRs has the potential to improve the treatment of several diseases with unmet medical needs.


   Company Address: 19925 Stevens Creek Blvd., Suite 100 Cupertino 95014 CA
   Company Phone Number: 501-8881   Stock Exchange / Ticker: NASDAQ RVPH
   RVPH is expected to report next financial results on March 29, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

A Deep Dive into Brilaroxazine: Insights from Topline Data Analysis of the Phase 3 RECOVER Trial in Schizophrenia

Published Tue, Feb 6 2024 1:00 PM UTC

is pleased to present an exclusive analysis of the topline data from the Phase 3 RECOVER Trial of Brilaroxazine in schizophrenia. This groundbreaking study, conducted by pharmaceutical company Reviva, promises significant advancements in the treatment of this complex mental disorder. To shed light on the trial's findings, a virtual event will be hosted on Thursday, February...

Reviva Pharmaceuticals Holdings Inc

Reviva Pharmaceuticals Holdings Inc. Reports Operating Loss in Third Quarter of 2023


As a financial journalist for The , I have been closely monitoring the recent financial results of the Major Pharmaceutical Preparations industry, particularly focusing on Reviva Pharmaceuticals Holdings Inc. The third quarter of 2023 has provided some interesting insights into the company's performance and its future prospects.
Starting with the operating loss of $-10.709047 million, it is evident that Reviva Pharmaceuticals Holdings Inc has faced significant challenges in the recent reporting season. What's more alarming is the absence of any specified revenue, raising concerns among industry advisors. However, these numbers do not deter market analysts, as they anticipate additional revenue sources to materialize in the near future.

Reviva Pharmaceuticals Holdings Inc

Reviva Pharmaceuticals Holdings Inc Faces Disappointing Operating Deficit, Urgently Seeking New Revenue Streams

Reviva Pharmaceuticals Holdings Inc Faces Operating Deficit, Company Seeking New Revenue Sources
In a surprising turn of events, Reviva Pharmaceuticals Holdings Inc, a major pharmaceutical preparations company, has encountered an operating deficit of $-12.070551 million during the April to June 2023 period. This comes as a disappointment to shareholders who had not expected any adjustments in revenue during the earnings season. This operating deficit is a significant deterioration from the $-5.519488 million deficit reported in the second quarter of 2022.
While shareholders had hoped for better financial results, analysts are now speculating when the company will start to show growth in their top-line. The management is actively seeking various business models in order to ensure a constant stream of revenue sources.
Furthermore, the shortfalls in revenue have continued to increase over the same period, with the company reporting a deficit of $-12.443 million compared to $-5.341 million in the corresponding period a year ago. These financial challenges indicate a need for Reviva Pharmaceuticals Holdings Inc to strategize and address their revenue generation methods.

Reviva Pharmaceuticals Holdings Inc

Reviva Pharmaceuticals Holdings Inc Reports Significant Net Losses in First Quarter 2023, Raising Concerns for Investors

As a journalist, one of my key responsibilities is to interpret financial results for my readers. Today, I am analyzing the first quarter 2023 earnings report of Reviva Pharmaceuticals Holdings Inc, a major player in the pharmaceutical preparations industry.
According to the report, the company recorded a cumulative net loss of $-24 million during the 12-month period ending in the first quarter 2023. This resulted in a negative return on equity (ROE) of -172.97%, which is not a positive sign for the company's investors.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com